Promomed Group of Companies has registered the first drug in its portfolio for the treatment of HIV infection

Ritonavir, used for the treatment of HIV infection and viral hepatitis C, has received a registration certificate, becoming the first drug in the Promomed Group's antiretroviral portfolio.

Ritonavir is an antiviral drug that disrupts the formation of viral proteins, the effectiveness and safety of which has been well studied and proven in the combination therapy of HIV infection and viral hepatitis C. Thanks to the use of these antiviral treatment regimens, it has become possible to suppress viral infection in the early stages, reduce the risk of HIV transmission to healthy people, eliminate the risk of liver cirrhosis and life-threatening complications., including liver cancer, which helps to increase the life expectancy of patients and preserve its quality.

One of the most important strategic directions in the work of Promomed Group, focused on solving significant medical problems, saving and significantly improving the quality of life of patients, is the development and production of drugs aimed at treating major critical diseases, including the human immunodeficiency virus.

"The HIV epidemic in Russia can be stopped only through the joint efforts of all market participants. Our company couldn't stay away. Antiviral therapy is the key to the success of treatment of patients with HIV infection, helps to increase the duration and maintain the quality of life of patients. The release of this drug is only the first step of the Promomed group towards the development of a line of drugs for the treatment of HIV," she said.Kira Zaslavskaya, Director of New Products, Promomed Group.

Ritonavir will be available in the form of capsules with a dosage of 100 mg, which corresponds to the required intake regimens. The drug is included in the list of VED.